drugset / Trial / NCT02974933
Apatinib Mesylate Combined With Pemetrexed in the Treatment of Pretreated Advanced Non-squamous Non-small Cell Lung Cancer
Phase 2
Unknown
48 enrolled
Wuling Ou
Hubei Clinical Research Collaboration Group · collabJiangsu HengRui Medicine Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the efficacy of apatinib mesylate combined with pemetrexed alone in advanced non-small cell lung cancer patients in the second or second line of treatment of progression-free survival
Timeline
- Start
- 2016-11
- Primary completion
- 2017-11
- Completion
- 2018-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pemetrexed | Small molecule | — | — |
| Subject | Rivoceranib | Small molecule | 500 mg | Oral |